How Seladelpar Works: A New Approach to Primary Biliary Cholangitis Treatment │ Pharmacology

Discover how Seladelpar, a selective PPARδ agonist, is revolutionizing the treatment of primary biliary cholangitis. Learn about its unique mechanism of action in regulating bile acid metabolism and reducing liver inflammation. Explore the key clinical trial results that led to seladelpar's FDA approval.

Disclaimer:
This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease.

References:
4. Barba Bernal R, Ferrigno B, Medina Morales E, et al. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives. Turk J Gastroenterol. 2023;34(2):89-100. doi:10.5152/tjg.2023.22239
6. Hirschfield GM, Bowlus CL, Mayo MJ, et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024;390(9):783-794. doi:10.1056/NEJMoa2312100

#seladelpar #primarybiliarycholangitis #PBC #liverdisease #bileacids #treatment #clinicaltrials #FDAapproval #healthcare #medical #health #science